Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBT101 in patients with solid tumors after curative surgery
NCT04557306Phase 1Completed
- Sponsor
- CHA Biotech
- Start
- Sep 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vebreltinib in solid tumor (2 arms), sponsored by CHA Biotech. Primary endpoint: Dose limiting toxicity at 29 days. Started Sep 2020; status: completed.
02
Drugs
vebreltinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04557306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04557306.